PMC:7589163 / 87911-88402 JSONTXT

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T179","span":{"begin":264,"end":270},"obj":"Body_part"}],"attributes":[{"id":"A179","pred":"uberon_id","subj":"T179","obj":"http://purl.obolibrary.org/obo/UBERON_0016552"}],"text":"Prenatal Docosahexaenoic Acid Supplementation and Infant Morbidity: Randomized Controlled Trial. Imhoff-Kunsch et al., 2011 [213] Pregnant woman; a total of more of 800 infants were included in the trial.RCT DHA (400 mg) At 1 month: shorter duration of cough, phlegm, and wheezing, respectively (p \u003c 0.001). At 3 months: 14% less time ill (p \u003c 0.0001). At 6 months: shorter duration of fever, nasal secretion, difficulty breathing, rash, and “other illness,” respectively (all p \u003c 0.05)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T786","span":{"begin":148,"end":149},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T787","span":{"begin":225,"end":229},"obj":"http://purl.obolibrary.org/obo/CLO_0001757"}],"text":"Prenatal Docosahexaenoic Acid Supplementation and Infant Morbidity: Randomized Controlled Trial. Imhoff-Kunsch et al., 2011 [213] Pregnant woman; a total of more of 800 infants were included in the trial.RCT DHA (400 mg) At 1 month: shorter duration of cough, phlegm, and wheezing, respectively (p \u003c 0.001). At 3 months: 14% less time ill (p \u003c 0.0001). At 6 months: shorter duration of fever, nasal secretion, difficulty breathing, rash, and “other illness,” respectively (all p \u003c 0.05)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T15770","span":{"begin":25,"end":29},"obj":"Chemical"},{"id":"T18406","span":{"begin":211,"end":214},"obj":"Chemical"}],"attributes":[{"id":"A17347","pred":"chebi_id","subj":"T15770","obj":"http://purl.obolibrary.org/obo/CHEBI_37527"},{"id":"A31101","pred":"chebi_id","subj":"T18406","obj":"http://purl.obolibrary.org/obo/CHEBI_16016"},{"id":"A35728","pred":"chebi_id","subj":"T18406","obj":"http://purl.obolibrary.org/obo/CHEBI_28125"},{"id":"A93673","pred":"chebi_id","subj":"T18406","obj":"http://purl.obolibrary.org/obo/CHEBI_28689"},{"id":"A81860","pred":"chebi_id","subj":"T18406","obj":"http://purl.obolibrary.org/obo/CHEBI_36005"}],"text":"Prenatal Docosahexaenoic Acid Supplementation and Infant Morbidity: Randomized Controlled Trial. Imhoff-Kunsch et al., 2011 [213] Pregnant woman; a total of more of 800 infants were included in the trial.RCT DHA (400 mg) At 1 month: shorter duration of cough, phlegm, and wheezing, respectively (p \u003c 0.001). At 3 months: 14% less time ill (p \u003c 0.0001). At 6 months: shorter duration of fever, nasal secretion, difficulty breathing, rash, and “other illness,” respectively (all p \u003c 0.05)."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T168","span":{"begin":403,"end":412},"obj":"http://purl.obolibrary.org/obo/GO_0046903"},{"id":"T169","span":{"begin":425,"end":434},"obj":"http://purl.obolibrary.org/obo/GO_0007585"}],"text":"Prenatal Docosahexaenoic Acid Supplementation and Infant Morbidity: Randomized Controlled Trial. Imhoff-Kunsch et al., 2011 [213] Pregnant woman; a total of more of 800 infants were included in the trial.RCT DHA (400 mg) At 1 month: shorter duration of cough, phlegm, and wheezing, respectively (p \u003c 0.001). At 3 months: 14% less time ill (p \u003c 0.0001). At 6 months: shorter duration of fever, nasal secretion, difficulty breathing, rash, and “other illness,” respectively (all p \u003c 0.05)."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T261","span":{"begin":257,"end":262},"obj":"Phenotype"},{"id":"T262","span":{"begin":276,"end":284},"obj":"Phenotype"},{"id":"T263","span":{"begin":390,"end":395},"obj":"Phenotype"},{"id":"T264","span":{"begin":414,"end":434},"obj":"Phenotype"},{"id":"T265","span":{"begin":436,"end":440},"obj":"Phenotype"}],"attributes":[{"id":"A261","pred":"hp_id","subj":"T261","obj":"http://purl.obolibrary.org/obo/HP_0012735"},{"id":"A262","pred":"hp_id","subj":"T262","obj":"http://purl.obolibrary.org/obo/HP_0030828"},{"id":"A263","pred":"hp_id","subj":"T263","obj":"http://purl.obolibrary.org/obo/HP_0001945"},{"id":"A264","pred":"hp_id","subj":"T264","obj":"http://purl.obolibrary.org/obo/HP_0002098"},{"id":"A265","pred":"hp_id","subj":"T265","obj":"http://purl.obolibrary.org/obo/HP_0000988"}],"text":"Prenatal Docosahexaenoic Acid Supplementation and Infant Morbidity: Randomized Controlled Trial. Imhoff-Kunsch et al., 2011 [213] Pregnant woman; a total of more of 800 infants were included in the trial.RCT DHA (400 mg) At 1 month: shorter duration of cough, phlegm, and wheezing, respectively (p \u003c 0.001). At 3 months: 14% less time ill (p \u003c 0.0001). At 6 months: shorter duration of fever, nasal secretion, difficulty breathing, rash, and “other illness,” respectively (all p \u003c 0.05)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T578","span":{"begin":0,"end":67},"obj":"Sentence"},{"id":"T579","span":{"begin":68,"end":96},"obj":"Sentence"},{"id":"T580","span":{"begin":98,"end":311},"obj":"Sentence"},{"id":"T581","span":{"begin":312,"end":324},"obj":"Sentence"},{"id":"T582","span":{"begin":325,"end":356},"obj":"Sentence"},{"id":"T583","span":{"begin":357,"end":491},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Prenatal Docosahexaenoic Acid Supplementation and Infant Morbidity: Randomized Controlled Trial. Imhoff-Kunsch et al., 2011 [213] Pregnant woman; a total of more of 800 infants were included in the trial.RCT DHA (400 mg) At 1 month: shorter duration of cough, phlegm, and wheezing, respectively (p \u003c 0.001). At 3 months: 14% less time ill (p \u003c 0.0001). At 6 months: shorter duration of fever, nasal secretion, difficulty breathing, rash, and “other illness,” respectively (all p \u003c 0.05)."}

{"project":"LitCovid-PubTator","denotations":[{"id":"3572","span":{"begin":141,"end":146},"obj":"Species"},{"id":"3573","span":{"begin":171,"end":178},"obj":"Species"},{"id":"3601","span":{"begin":9,"end":29},"obj":"Chemical"},{"id":"3602","span":{"begin":211,"end":214},"obj":"Chemical"},{"id":"3632","span":{"begin":257,"end":262},"obj":"Disease"},{"id":"3633","span":{"begin":390,"end":395},"obj":"Disease"},{"id":"3634","span":{"begin":436,"end":440},"obj":"Disease"}],"attributes":[{"id":"A3572","pred":"tao:has_database_id","subj":"3572","obj":"Tax:9606"},{"id":"A3573","pred":"tao:has_database_id","subj":"3573","obj":"Tax:9606"},{"id":"A3601","pred":"tao:has_database_id","subj":"3601","obj":"MESH:D004281"},{"id":"A3602","pred":"tao:has_database_id","subj":"3602","obj":"MESH:C027493"},{"id":"A3632","pred":"tao:has_database_id","subj":"3632","obj":"MESH:D003371"},{"id":"A3633","pred":"tao:has_database_id","subj":"3633","obj":"MESH:D005334"},{"id":"A3634","pred":"tao:has_database_id","subj":"3634","obj":"MESH:D005076"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Prenatal Docosahexaenoic Acid Supplementation and Infant Morbidity: Randomized Controlled Trial. Imhoff-Kunsch et al., 2011 [213] Pregnant woman; a total of more of 800 infants were included in the trial.RCT DHA (400 mg) At 1 month: shorter duration of cough, phlegm, and wheezing, respectively (p \u003c 0.001). At 3 months: 14% less time ill (p \u003c 0.0001). At 6 months: shorter duration of fever, nasal secretion, difficulty breathing, rash, and “other illness,” respectively (all p \u003c 0.05)."}